Sunitinib for Treatment of Advanced Renal Cell Cancer: Primary Tumor Response

Purpose: Nephrectomy before immunotherapy in patients with metastatic renal cell cancer (RCC) will improve patient outcome. In addition, the primary tumor is known to be refractory to cytokines. Sunitinib is now approved for treatment of advanced RCC, but its effect on the primary tumor has yet to b...

Full description

Saved in:

Bibliographic Details
Published in:	Clinical cancer research Vol. 14; no. 8; pp. 2431 - 2436
Main Authors:	VAN DER VELDT, Astrid A. M, MEIJERINK, Martijn R, VAN DEN EERTWEGH, Alfons J. M, BEX, Axel, DE GAST, Gijsbert, HAANEN, John B. A. G, BOVEN, Epie
Format:	Journal Article
Language:	English
Published:	Philadelphia, PA American Association for Cancer Research 15-04-2008
Subjects:	Aged Antineoplastic agents Antineoplastic Agents - therapeutic use Biological and medical sciences Carcinoma, Renal Cell - diagnostic imaging Carcinoma, Renal Cell - drug therapy Female Humans Indoles - therapeutic use Kidney Neoplasms - diagnostic imaging Kidney Neoplasms - drug therapy Kidneys Male Medical sciences Middle Aged Nephrectomy Nephrology. Urinary tract diseases Pharmacology. Drug treatments primary tumor Pyrroles - therapeutic use renal cell cancer sunitinib Tomography, X-Ray Computed Tumors of the urinary system Kidney disease Urinary system disease Carcinoma Enzyme Tyrosine kinase inhibitor Transferases Enzyme inhibitor Malignant tumor Sunitinib Treatment Kidney cancer Primary Grawitz tumor Advanced stage Multikinase inhibitor Protein-tyrosine kinase Cancer
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!